美股A股
StockGist
Back
8-K2026-05-13· deepseek-chat

DYAI · Dyadic International, Inc.

0001493152-26-022727

SEC filing

Summary

Dyadic International reported Q1 2026 revenue of $1.11M, up 182% YoY, and net loss of $1.95M, improved from $2.03M, driven by higher grant and license revenue.

Key takeaways

Full analysis

Dyadic International's Q1 2026 results reflect a company transitioning from R&D to commercial stage. Revenue increased 182% to $1.11 million, driven by a $220,490 rise in R&D revenue (primarily from the Proliant agreement), a $276,894 increase in grant revenue (CEPI and Gates Foundation), and a $200,000 license milestone from Inzymes. Cost of revenue rose 166% to $791,840, largely due to higher grant-related costs. R&D expenses decreased 3.8% to $476,069, while G&A expenses increased 10% to $1.76 million, mainly from legal and accounting costs. The operating loss improved 5% to $1.90 million, and net loss per share narrowed from $(0.07) to $(0.05). Cash and securities totaled $6.6 million, down from $8.6 million at year-end 2025, reflecting cash burn. Management highlighted commercial milestones: initial purchase orders for recombinant bovine transferrin, commercial launch of AlbuFree DX by Proliant, expanded collaboration with Fermbox Bio, and an OEM distribution agreement with IBT Bioservices. The Gates Foundation and CEPI programs are advancing toward preclinical evaluation. No forward guidance was provided. The results indicate progress in revenue diversification and commercial execution, though cash burn remains a concern.